Secondary Impact of the Coronavirus Disease 19 Pandemic on Patients and the Cellular Therapy Healthcare Ecosystem

Jane Koo; Jeffrey J. Auletta; David M. Hartley; John Huber; Samantha Jaglowski; Malika Kapadia; Katilyn Kusnier; Leslie Lehmann; Joseph Maakaron; Kasiani C. Myers; Ahna Pai; Loretta Parker; Rachel A Phelan; Christine Sper; Seth J. Rotz; Christopher E. Dandoy

doi:10.1016/j.jtct.2022.07.020

Secondary Impact of the Coronavirus Disease 19 Pandemic on Patients and the Cellular Therapy Healthcare Ecosystem

Jane Koo, Jeffrey J. Auletta, David M. Hartley, John Huber, Samantha Jaglowski, Malika Kapadia, Katilyn Kusnier, Leslie Lehmann, Joseph Maakaron, Kasiani C. Myers, Ahna Pai, Loretta Parker, Rachel A Phelan, Christine Sper, Seth J. Rotz, Christopher E. Dandoy

Medicine - Hematology, Oncology, Transplant

Research output: Contribution to journal › Review article › peer-review

Abstract

The Coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has significantly impacted global health and healthcare delivery systems. To characterize the secondary effects of the COVID-19 pandemic and mitigation strategies used in the delivery of hematopoietic stem cell transplantation (HSCT) care, we performed a comprehensive literature search encompassing changes in specific donor collection, processing practices, patient outcomes, and patient-related concerns specific to HSCT and HSCT-related healthcare delivery. In this review, we summarize the available literature on the secondary impacts the COVID-19 pandemic on the fields of HSCT and cellular therapy. The COVID-19 pandemic has had numerous secondary impacts on patients undergoing HSCT and the healthcare delivery systems involved in providing complex care to HSCT recipients. Institutions must identify these influences on outcomes and adjust accordingly to maintain and improve outcomes for the transplantation and cellular therapy community.

Original language	English (US)
Pages (from-to)	737-746
Number of pages	10
Journal	Transplantation and Cellular Therapy
Volume	28
Issue number	11
DOIs	https://doi.org/10.1016/j.jtct.2022.07.020
State	Published - Nov 2022

Bibliographical note

Funding Information:
Financial disclosure: S.R. received support from the National Center for Advancing Translational Sciences (2KL2TR002547; Raed Dweik, principal investigator). Conflict of interest statement: R.P. reports serving on an advisory board for bluebird bio and receipt of research funding from Amgen. C.D. reports honoraria from Omeros and Alexion Pharmaceuticals. The other authors have no conflicts of interest to report. Financial disclosure: See Acknowledgments on page XXX.

Funding Information:
Financial disclosure: S.R. received support from the National Center for Advancing Translational Sciences (2KL2TR002547; Raed Dweik, principal investigator).

Publisher Copyright:
© 2022 The American Society for Transplantation and Cellular Therapy

Keywords

COVID-19
Cell therapy
Coronavirus
Cryopreservation
Healthcare delivery
Hematopoietic stem cell transplantation
Mitigation strategies
SARS-CoV-2
Severe acute respiratory syndrome

PubMed: MeSH publication types

Journal Article
Review
Research Support, N.I.H., Extramural

Publisher link

10.1016/j.jtct.2022.07.020

Find It

Find It at U of M Libraries

Cite this

Koo, J., Auletta, J. J., Hartley, D. M., Huber, J., Jaglowski, S., Kapadia, M., Kusnier, K., Lehmann, L., Maakaron, J., Myers, K. C., Pai, A., Parker, L., Phelan, R. A., Sper, C., Rotz, S. J., & Dandoy, C. E. (2022). Secondary Impact of the Coronavirus Disease 19 Pandemic on Patients and the Cellular Therapy Healthcare Ecosystem. Transplantation and Cellular Therapy, 28(11), 737-746. https://doi.org/10.1016/j.jtct.2022.07.020

Koo, J, Auletta, JJ, Hartley, DM, Huber, J, Jaglowski, S, Kapadia, M, Kusnier, K, Lehmann, L, Maakaron, J, Myers, KC, Pai, A, Parker, L, Phelan, RA, Sper, C, Rotz, SJ & Dandoy, CE 2022, 'Secondary Impact of the Coronavirus Disease 19 Pandemic on Patients and the Cellular Therapy Healthcare Ecosystem', Transplantation and Cellular Therapy, vol. 28, no. 11, pp. 737-746. https://doi.org/10.1016/j.jtct.2022.07.020

@article{4d1ff8551acb42c48fd91042358b0ef0,

title = "Secondary Impact of the Coronavirus Disease 19 Pandemic on Patients and the Cellular Therapy Healthcare Ecosystem",

abstract = "The Coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has significantly impacted global health and healthcare delivery systems. To characterize the secondary effects of the COVID-19 pandemic and mitigation strategies used in the delivery of hematopoietic stem cell transplantation (HSCT) care, we performed a comprehensive literature search encompassing changes in specific donor collection, processing practices, patient outcomes, and patient-related concerns specific to HSCT and HSCT-related healthcare delivery. In this review, we summarize the available literature on the secondary impacts the COVID-19 pandemic on the fields of HSCT and cellular therapy. The COVID-19 pandemic has had numerous secondary impacts on patients undergoing HSCT and the healthcare delivery systems involved in providing complex care to HSCT recipients. Institutions must identify these influences on outcomes and adjust accordingly to maintain and improve outcomes for the transplantation and cellular therapy community.",

keywords = "COVID-19, Cell therapy, Coronavirus, Cryopreservation, Healthcare delivery, Hematopoietic stem cell transplantation, Mitigation strategies, SARS-CoV-2, Severe acute respiratory syndrome",

author = "Jane Koo and Auletta, {Jeffrey J.} and Hartley, {David M.} and John Huber and Samantha Jaglowski and Malika Kapadia and Katilyn Kusnier and Leslie Lehmann and Joseph Maakaron and Myers, {Kasiani C.} and Ahna Pai and Loretta Parker and Phelan, {Rachel A} and Christine Sper and Rotz, {Seth J.} and Dandoy, {Christopher E.}",

note = "Funding Information: Financial disclosure: S.R. received support from the National Center for Advancing Translational Sciences (2KL2TR002547; Raed Dweik, principal investigator). Conflict of interest statement: R.P. reports serving on an advisory board for bluebird bio and receipt of research funding from Amgen. C.D. reports honoraria from Omeros and Alexion Pharmaceuticals. The other authors have no conflicts of interest to report. Financial disclosure: See Acknowledgments on page XXX. Funding Information: Financial disclosure: S.R. received support from the National Center for Advancing Translational Sciences (2KL2TR002547; Raed Dweik, principal investigator). Publisher Copyright: {\textcopyright} 2022 The American Society for Transplantation and Cellular Therapy",

year = "2022",

month = nov,

doi = "10.1016/j.jtct.2022.07.020",

language = "English (US)",

volume = "28",

pages = "737--746",

journal = "Transplantation and Cellular Therapy",

issn = "2666-6375",

publisher = "Elsevier BV",

number = "11",

}

TY - JOUR

T1 - Secondary Impact of the Coronavirus Disease 19 Pandemic on Patients and the Cellular Therapy Healthcare Ecosystem

AU - Koo, Jane

AU - Auletta, Jeffrey J.

AU - Hartley, David M.

AU - Huber, John

AU - Jaglowski, Samantha

AU - Kapadia, Malika

AU - Kusnier, Katilyn

AU - Lehmann, Leslie

AU - Maakaron, Joseph

AU - Myers, Kasiani C.

AU - Pai, Ahna

AU - Parker, Loretta

AU - Phelan, Rachel A

AU - Sper, Christine

AU - Rotz, Seth J.

AU - Dandoy, Christopher E.

N1 - Funding Information: Financial disclosure: S.R. received support from the National Center for Advancing Translational Sciences (2KL2TR002547; Raed Dweik, principal investigator). Conflict of interest statement: R.P. reports serving on an advisory board for bluebird bio and receipt of research funding from Amgen. C.D. reports honoraria from Omeros and Alexion Pharmaceuticals. The other authors have no conflicts of interest to report. Financial disclosure: See Acknowledgments on page XXX. Funding Information: Financial disclosure: S.R. received support from the National Center for Advancing Translational Sciences (2KL2TR002547; Raed Dweik, principal investigator). Publisher Copyright: © 2022 The American Society for Transplantation and Cellular Therapy

PY - 2022/11

Y1 - 2022/11

N2 - The Coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has significantly impacted global health and healthcare delivery systems. To characterize the secondary effects of the COVID-19 pandemic and mitigation strategies used in the delivery of hematopoietic stem cell transplantation (HSCT) care, we performed a comprehensive literature search encompassing changes in specific donor collection, processing practices, patient outcomes, and patient-related concerns specific to HSCT and HSCT-related healthcare delivery. In this review, we summarize the available literature on the secondary impacts the COVID-19 pandemic on the fields of HSCT and cellular therapy. The COVID-19 pandemic has had numerous secondary impacts on patients undergoing HSCT and the healthcare delivery systems involved in providing complex care to HSCT recipients. Institutions must identify these influences on outcomes and adjust accordingly to maintain and improve outcomes for the transplantation and cellular therapy community.

AB - The Coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has significantly impacted global health and healthcare delivery systems. To characterize the secondary effects of the COVID-19 pandemic and mitigation strategies used in the delivery of hematopoietic stem cell transplantation (HSCT) care, we performed a comprehensive literature search encompassing changes in specific donor collection, processing practices, patient outcomes, and patient-related concerns specific to HSCT and HSCT-related healthcare delivery. In this review, we summarize the available literature on the secondary impacts the COVID-19 pandemic on the fields of HSCT and cellular therapy. The COVID-19 pandemic has had numerous secondary impacts on patients undergoing HSCT and the healthcare delivery systems involved in providing complex care to HSCT recipients. Institutions must identify these influences on outcomes and adjust accordingly to maintain and improve outcomes for the transplantation and cellular therapy community.

KW - COVID-19

KW - Cell therapy

KW - Coronavirus

KW - Cryopreservation

KW - Healthcare delivery

KW - Hematopoietic stem cell transplantation

KW - Mitigation strategies

KW - SARS-CoV-2

KW - Severe acute respiratory syndrome

UR - http://www.scopus.com/inward/record.url?scp=85136675259&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85136675259&partnerID=8YFLogxK

U2 - 10.1016/j.jtct.2022.07.020

DO - 10.1016/j.jtct.2022.07.020

M3 - Review article

C2 - 35902050

AN - SCOPUS:85136675259

SN - 2666-6375

VL - 28

SP - 737

EP - 746

JO - Transplantation and Cellular Therapy

JF - Transplantation and Cellular Therapy

IS - 11

ER -

Secondary Impact of the Coronavirus Disease 19 Pandemic on Patients and the Cellular Therapy Healthcare Ecosystem

Abstract

Bibliographical note

Keywords

PubMed: MeSH publication types

Publisher link

Find It

Other files and links

Fingerprint

Cite this